Home
NewsNewsWith ART Fertility Clinics now part of its network, IVI RMA Global has created a Middle East operating region to meet growing fertility needs. The integration boosts treatment capacity, scientific output, and care consistency across the UAE and Saudi Arabia as demographic pressures shape demand for assisted reproduction
IVI RMA Global has named the Middle East as its newest operating region after acquiring ART Fertility Clinics, a move that marks an important step in the IVI RMA Global expansion into fast-growing reproductive markets. The integration covers ART Fertility’s established operations in the UAE and its planned entry into Saudi Arabia, extending the company’s network beyond North America, Italy, Northern Europe, Iberia, Latam, and Czechia. Led by CEO Suresh Soni and Medical Director Dr. Human M. Fatemi, the move positions the combined platform to serve tens of thousands of patients across the region.
The expansion comes as the Middle East faces declining fertility rates, with World Bank data showing the UAE at 1.2 births per woman and continued declines in Saudi Arabia. Dr. Fatemi said, “Across the Middle East, there is a growing awareness of the importance of addressing fertility challenges directly, and we are seeing more individuals and couples seeking advanced solutions every day,” adding that ART Fertility’s integration will accelerate scientific progress and raise care standards. The acquisition strengthens the IVI RMA Global expansion strategy by bringing more than 300 clinicians, embryologists, and geneticists into its network, supported by proprietary research and protocols that have delivered pregnancy rates as high as 71% across multiple age groups.
Soni noted, “The entire ART Fertility team is excited about this combination of two leaders in global fertility meeting the fertility challenge in the Middle East,” highlighting opportunities to deepen clinical value and research output. ART Fertility’s scientific footprint stretches across major R&D investments, more than 268 peer-reviewed papers, 35 ongoing studies, and 11 conferences. Together, these efforts have helped cement its role as a reference point in reproductive medicine. These capabilities align with the broader IVI RMA Global expansion effort aimed at advancing fertility science and strengthening clinical practice across the region.
Javier Sánchez Prieto, CEO of IVI RMA Global, said, “We are always looking for quality organizations that meet our high standards and whose own success can strengthen our work,” emphasizing the expectation that demand for fertility care in the Middle East will continue to grow. The acquisition places IVI RMA in a strong position to lead scientific and clinical advancements throughout the region.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
